Identifying Insulin Autoantibodies With Differential Risk in Type 1 Diabetes With a Novel Bridging ELISA
Diabetes · 2026
DOI: 10.2337/db25-0696 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2026. Verfasst von Xiaofan Jia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Barbara Davis Center for Diabetes, University of Colorado, Aurora, CO. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin Antibodies, Autoantibodies, Insulin. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Breakthrough T1D, Diabetes Research Center.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Insulin autoantibodies (IAAs) are commonly measured by radiobinding assays (RBAs), which detect both high- and low-affinity binding. Improved assays that preferentially detect high-affinity IAA are likely to provide greater specificity and thereby increase the diagnostic accuracy of IAA for early-stage type 1 diabetes (T1D). This study aimed to develop and validate a novel bridging ELISA for IAA detection. The bridging ELISA detects IAAs by their bivalent cross-linking of two proinsulin moieties in fluid phase. Validation was performed by using samples from 227 patients with newly diagnosed stage 3 T1D and 1,021 control participants. Additionally, 202 children positive for IAA by RBA from general population screening were tested by the bridging ELISA and electrochemiluminescence (ECL) assay. At 99.5% specificity, ELISA detected IAA in 65.2% of patients with stage 3 T1D vs. 60.8% by RBA. Among children identified as having RBA-positive IAA in general population screening, 80.3% of those with multiple islet autoantibodies and 48.1% of those with a single IAA had ELISA-IAA positive findings (P < 0.0001). For children with a single IAA by RBA, ELISA detected 78.9% of those with ECL-IAA–positive findings vs. 27.9% of those with ECL-IAA negative findings (P < 0.0001). Samples that were IAA negative by ELISA showed lower antibody affinity. The ELISA-IAA assay demonstrates high sensitivity and specificity and could become a practical tool for T1D population screening and clinical diagnosis across laboratories. Article Highlights In global type 1 diabetes (T1D) population screening studies, there is an urgent need for a highly sensitive and specific insulin autoantibody (IAA) assay that can be implemented across multiple laboratories. This study aimed to develop and characterize a novel ELISA-based platform for IAA detection. We established a new bridging ELISA for IAA and validated it in cohorts of patients with stage 3 T1D, children positive for multiple and single islet antibodies, and control children negative for islet autoantibodies. The bridging ELISA-IAA assay demonstrates excellent sensitivity and specificity, preferentially identifies high-risk individuals, and offers a practical, scalable solution for T1D population screening and clinical diagnosis across laboratories.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Barbara Davis Center for Diabetes, University of Colorado, Aurora, CO.
ORCID-Profile: Xiaofan Jia, Aaron W Michels, Liping Yu
Förderung
- NIDDK NIH HHS
- Breakthrough T1D
- Diabetes Research Center
Zitieren
APA
Jia, X., Zhang, C., Waugh, K., Miao, D., Michels, A. W., Rewers, M. J., & Yu, L. (2026). Identifying Insulin Autoantibodies With Differential Risk in Type 1 Diabetes With a Novel Bridging ELISA. Diabetes. https://doi.org/10.2337/db25-0696
Vancouver
Jia X, Zhang C, Waugh K, Miao D, Michels AW, Rewers MJ, et al. Identifying Insulin Autoantibodies With Differential Risk in Type 1 Diabetes With a Novel Bridging ELISA. Diabetes. 2026. doi:10.2337/db25-0696
BibTeX
@article{Jia2026,
author = {Jia, Xiaofan and Zhang, Caiguo and Waugh, Kathleen and Miao, Dongmei and Michels, Aaron W and Rewers, Marian J and Yu, Liping},
title = {Identifying Insulin Autoantibodies With Differential Risk in Type 1 Diabetes With a Novel Bridging ELISA},
journal = {Diabetes},
year = {2026},
doi = {10.2337/db25-0696}
}
EUVIMED